Compare Bumble Inc (BMBL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bumble Inc vs BIO-TECHNE Corp — how do they compare? Bumble Inc trades at $2.77 (market cap $359.61M), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 31.3× Bumble Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Bumble Inc pays none. Which is the better fit depends on your goals.
| BMBL | TECH | |
|---|---|---|
Market Cap | $359.61M | $11.24B |
Sector | Technology | Health |
52-Week High | $7.17 | $72.29 |
52-Week Low | $2.70 | $43.31 |
Enterprise Value | $665.47M | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bumble (BMBL) trades at $2.83, down 0.53% with bearish technical signals. The company reported mixed Q2 2026 results, beating earnings estimates but missing on revenue with declining paying users. Despite a gross margin of 72.84%, Bumble shows negative profitability metrics with -57.96% net margin and -87.65% ROE. Recent news indicates strategic shifts toward IRL events and AI matchmaking amid exploration of potential sale options.
Outlook remains challenging with significant execution risks. While valuation multiples appear attractive (P/S 0.39, P/B 0.72), persistent user declines and negative cash flow create headwinds. Analyst consensus leans Hold (73.91%) with $3.62 price target suggesting 28% upside, but success hinges on product transformation reversing user trends.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bumble Inc
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
